ADPT250117P2500
- 0.05
- 0.000.00%
Adaptive Biotechnologies Newsroom
Adaptive Biotechnologies Analyst Ratings
BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $9
Morgan Stanley Maintains Adaptive Biotechnologies(ADPT.US) With Hold Rating, Maintains Target Price $7
Morgan Stanley Maintains Adaptive Biotechnologies(ADPT.US) With Hold Rating, Maintains Target Price $7
Balanced Hold Recommendation for Adaptive Biotechnologies Amid Positive Performance and External Challenges
Scotiabank Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $10
Adaptive Biotechnologies Is Maintained at Overweight by Piper Sandler
Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $7
J.P. Morgan Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $7
TD Cowen Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating
TD Cowen Reaffirms Their Buy Rating on Adaptive Biotechnologies (ADPT)
Goldman Sachs Initiates Adaptive Biotechnologies(ADPT.US) With Hold Rating, Announces Target Price $5.5
Adaptive Biotechnologies Analyst Ratings
BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $8
Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $6
Scotiabank Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $10
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX), Adaptive Biotechnologies (ADPT) and Rezolute (RZLT)
Scotiabank Sticks to Their Buy Rating for Adaptive Biotechnologies (ADPT)
Morgan Stanley Maintains Adaptive Biotechnologies(ADPT.US) With Hold Rating, Maintains Target Price $7
Adaptive Biotechnologies Analyst Ratings